Singapore, July 11 -- The Bio Investments Group AG (BIG), a Swiss healthcare-technology transfer platform, and South Korea-headquartered International Vaccine Institute (IVI), have announced the signing of a Memorandum of Understanding (MoU) to establish a strategic collaboration aimed at accelerating local vaccine manufacturing, clinical evidence generation, and capacity building across Africa and the Middle East.

This partnership underscores a shared vision to enhance global health security by fostering vaccine self-reliance in emerging markets, aligning BIG's execution and investment capabilities with IVI's technical guidance and global vaccine research, development, and regulatory expertise.

Key Areas of Cooperation under the MoU in...